Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.81 +2.60%

+$0.88 today

Market cap
$4.84B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 2.71M

Average 2.15M

COGT Common Stock Repurchased

Cash spent buying back the company's own shares.

Cogent Biosciences, Inc.NASDAQ: COGT

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased outflow grows to $0

Q2 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How COGT compares with its peers on the latest reported figures

  • COGT's LTM Jun 2026 common stock repurchased of $0 is the largest of the 10 companies compared; the peer median is $0.
COGT Competitors Peer median
Common Stock Repurchased for COGT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COGTCogent Biosciences, Inc.LTM Jun 2026$0 ———
INCYIncyte CorporationLTM Jun 2026$0 +100.0%—0.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 ———
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$0 ——0.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026$0 ——0.0%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
KURAKura Oncology, Inc.LTM Mar 2026$0 ——0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding COGT) $0+100.0%—0.0%

Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Depreciation & Amortization147K5.88M3.59M4.35M4.58M
Deferred Income Tax00000
Stock-Based Compensation11.69M18.37M30.62M39.74M46.08M
Change in Working Capital2.02M751K11.44M11.6M8.01M
Accounts Receivables00000
Inventory00000
Accounts Payables2.75M2.36M4.81M1.36M(2.51M)
Other Working Capital(731K)(1.61M)6.63M10.24M10.52M
Other Non-Cash Items(343K)(3.39M)(6.87M)(7.62M)5.82M
Operating Cash Flow(58.76M)(118.64M)(153.62M)(207.79M)(264.44M)
Capital Expenditures(1.72M)(6.86M)(2.8M)(573K)(1.55M)
Acquisitions (Net)0117.86K000
Purchases of Investments0(177.86M)(348.8M)(255.6M)(687.17M)
Sales of Investments060M253.78M294.45M289.2M
Other Investing Activities0(117.86K)000
Investing Cash Flow(1.72M)(124.72M)(97.82M)38.28M(399.53M)
Debt Repayment0000215.13M
Common Stock Issued38.01M161.95M161.82M213.34M712M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30K)1.61M01.12M(48.9M)
Financing Cash Flow37.98M163.56M163.54M214.45M878.23M
Effect of Forex Changes00000
Net Change in Cash(22.51M)(79.8M)(87.91M)44.94M214.26M
Free Cash Flow(60.48M)(125.5M)(156.42M)(208.36M)(266M)

Cogent Biosciences, Inc.

NASDAQ:COGT

Intrinsic Alpha fair value

Locked

Current Price

$27.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.